James Farrell
About James Farrell
James Farrell is the Director of WW HEOR Markets - Multiple Myeloma at Bristol Myers Squibb with over a decade of experience in health economics and outcomes research.
Current Role at Bristol Myers Squibb
James Farrell is currently serving as the Director of Worldwide Health Economics and Outcomes Research (HEOR) Markets for Multiple Myeloma at Bristol Myers Squibb. He joined this role in November 2020 and is responsible for leading HEOR strategies that support market access and the overall commercial success of treatments for Multiple Myeloma.
Previous Experience at Bristol Myers Squibb
Prior to his current role, James Farrell worked as the Associate Director of Worldwide HEOR Markets for Myeloid at Bristol Myers Squibb. This position, which he held for six months in 2020, involved developing and implementing HEOR strategies to support therapies targeting myeloid diseases.
Career at Celgene
James Farrell has an extensive career at Celgene where he held several key positions. From 2018 to 2020, he was the Head of Health Economics, Outcomes Research, and Pricing UK&I. Before this, he served as the Senior Manager for Pricing & Health Economics and Outcomes Research in Ireland in 2018. Farrell also completed a 12-month KAM secondment from 2017 to 2018 in Kent and worked as a Senior Health Economist from 2014 to 2018.
Roles at MSD
James Farrell worked in various capacities at MSD, significantly contributing to health economics and outcomes research. His roles included serving as the Senior HTA & OR Manager from 2013 to 2014, HTA and OR Manager from 2011 to 2013, and Associate Outcomes Research Manager from 2010 to 2011.
Educational Background
James Farrell holds an MSc in Economics & Health Economics from The University of Sheffield, earned from 2009 to 2010. Prior to that, he completed a BA (Hons) in Accounting, Economics, and Financial Management from the same university, graduating in 2009. His academic background equips him with a strong foundation in both economics and health economics, supporting his extensive career in health economics and outcomes research.